Commenting on the results of their meta-analysis, Holmes et al. suggest that CYP2C19 genotype does not affect clinical outcome in patients receiving clopidogrel therapy. However, we do not believe that the data support this conclusion; an association between genotype and outcome remains plausible and could be considered when choosing treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Snoep, J. D. et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154, 221–231 (2007).
Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D. & Casas, J. P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. A systematic review and meta-analysis. JAMA 306, 2704–2714 (2011).
Kazui, M. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38, 92–99 (2010).
Mega, J. L. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354–362 (2009).
Sibbing, D. et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J. Thromb. Haemost. 8, 1685–1693 (2010).
Mega, J. L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821–1830 (2010).
US Department of Health & Human Services. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. US Food and Drug Administration [online], (2010).
Wallentin, L. et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376, 1320–1328 (2010).
Paré, G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363, 1704–1714 (2010).
Mega, J. L. et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221–2228 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. M. ten Berg declares that he has acted as a speaker for Accumetrics, Eli Lilly, MSD and The Medicines Company. V. H Deneer declares no competing interests.
Rights and permissions
About this article
Cite this article
ten Berg, J., Deneer, V. Does CYP2C19 genotype affect clinical outcome?. Nat Rev Cardiol 9, 192–194 (2012). https://doi.org/10.1038/nrcardio.2012.29
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.29
This article is cited by
-
The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing
Cardiovascular Drugs and Therapy (2024)
-
Electrochemical immunosensor development based on core-shell high-crystalline graphitic carbon nitride@carbon dots and Cd0.5Zn0.5S/d-Ti3C2Tx MXene composite for heart-type fatty acid–binding protein detection
Microchimica Acta (2021)
-
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects
The Pharmacogenomics Journal (2013)
